Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Nov 05, 2024

BUY
$0.62 - $0.86 $603 - $837
974 New
974 $0
Q1 2024

May 15, 2024

SELL
$0.62 - $0.86 $7,926 - $10,994
-12,784 Reduced 92.92%
974 $0
Q4 2023

Feb 14, 2024

BUY
$0.7 - $1.31 $4,179 - $7,820
5,970 Added 76.66%
13,758 $11,000
Q3 2023

Nov 14, 2023

BUY
$1.25 - $3.0 $2,675 - $6,420
2,140 Added 37.89%
7,788 $10,000
Q2 2023

Aug 14, 2023

BUY
$1.73 - $2.79 $9,412 - $15,180
5,441 Added 2628.5%
5,648 $14,000
Q1 2023

May 15, 2023

BUY
$1.43 - $4.24 $296 - $877
207 New
207 $0
Q2 2022

Aug 15, 2022

BUY
$1.55 - $6.95 $1,550 - $6,950
1,000 New
1,000 $2,000

Others Institutions Holding VAXX

About Vaxxinity, Inc.


  • Ticker VAXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 112,150,000
  • Description
  • Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...
More about VAXX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.